BS_NB42PWZN
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 67.92
- os_event
- true
- age_years
- 18.342
- sex
- M
- race
- White
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.228590855
- umap2_2d
- 0.886355858
- umap1_3d
- 0.462162802
- umap2_3d
- 3.468504531
- umap3_3d
- -3.323682676
- dataset
- EPN-CBTN
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NB42PWZN | Supratentorial Ependymoma | — | 0.943 |
| 2 | SRR15030862 | — | — | 0.857 |
| 3 | f755bd47-f8ff-4847-9b8e-7d36b7b84155 | — | — | 0.821 |
| 4 | EPT0673 | EPN | EPN Tumor | 0.820 |
| 5 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.819 |
| 6 | SRR17866827 | — | — | 0.815 |
| 7 | 7478db87-0751-4771-941f-9fccdf01853d | — | — | 0.811 |
| 8 | BS_44A3ES23 | medulloblastoma | — | 0.808 |
| 9 | SJEPD001544_D1.RNA-Seq | EPN | Supratentorial EPN | 0.801 |
| 10 | SRR6013547 | — | cohortMD1 | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.010 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.010 | Inavolisib | — uncovered |